Zscaler ZS 深 沪
等待开盘 11-19 09:30:00 美东时间
293.11
-1.810
-0.61%
华盛通- 最 高297.999
- 今 开294.92
- 成交量 118.44万股
- 最 低 289.68
- 昨 收 294.92
- 总市值 463.11亿
- 52周最高 336.99
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 164.78
- 委 比 85.77%
- 总股本 1.58亿
- 历史最高 376.11
- 量 比 0.85
- 振 幅 2.82%
- 历史最低 24.76
- 每 手 1
- 风险率 48.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
33分钟前
Rosenblatt Maintains Buy on Zscaler, Raises Price Target to $365
Rosenblatt analyst Catharine Trebnick maintains Zscaler (NASDAQ:ZS) with a Buy and raises the price target from $330 to $365.
11-18 20:58
Zscaler Is a Proud Partner In The Microsoft Entra Agent ID Partner Ecosystem
Zscaler, a cloud security leader, has joined Microsoft's Entra Agent ID ecosystem as an early adopter. The partnership aims to enhance AI agent identity management and security, supporting scalable and safe AI adoption through Zero Trust principles. Zscaler will integrate with Microsoft's services and offer feedback to strengthen the platform. (228 characters)
11-18 20:00
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
Zscaler, Palo Alto Networks And A Financial Stock On CNBC's 'Final Trades'
On Friday, Raymond James Financial shares fell 1.5% and Zscaler fell 3%; but Palo Alto rose 0.2% to settle at $205.25.
11-17 20:51
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
Eli Lilly Stock Surges As Analyst Sees More Room To Run
Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to $1,104.
11-11 03:06
Palantir propels higher as enterprise software stocks show mixed reactions
Palantir (PLTR) shares jumped 7% by noon trading on Monday as the enterprise software sector showed mixed reactions following reports the U.S. Senate had struck a deal to remedy the government shutdow...
11-11 01:16
